<p>SINOPHARM (01099.HK) announced that its subsidiary SINOPHARM(CNCM LTD) (600511.SH) achieved an operating revenue of RMB 52.468 billion for the fiscal year 2025, an increase of 3.7% year-on-year. The net profit attributable to shareholders was RMB 1.997 billion, a slight decrease of 0.2%, with earnings per share of RMB 2.6462</p>

000028

588250

510660

<p>SINOPHARM announced that its subsidiary SINOPHARM(CNCM LTD) achieved an operating revenue of 52.468 billion RMB for the fiscal year 2025, an increase of 3.7% year-on-year. The net profit attributable to shareholders was 1.997 billion RMB, a slight decrease of 0.2%, with earnings per share of 2.6462 RMB</p>

AASTOCKS

Sinopharm Accord

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

SINOPHARM

SINOPHARM(CNCM LTD)

China Merchants CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

SINOPHARM's subsidiary SINOPHARM(CNCM LTD) earned 1.997 billion RMB for the year, a slight decrease of 0.2%